Saeed Sadeghi, MD


Associate Clinical Professor
Division of Hematology-Oncology
David Geffen School of Medicine
University of California
Los Angeles, CA 90095, USA

Biography

EDUCATION:

•(1991-1995) BS, University of California, Los Angeles
•(1995-1999) MD, St. Louis University School of Medicine

Internship

•(1999-2000) LAC/USC Medical Center, Keck School of Medicine at USC

Residency

•(2000-2002) LAC/USC Medical Center, Keck School of Medicine at USC

Fellowship-Hematology-Oncology

•(2002-2005) David Geffen School of Medicine at UCLA

PROFESSIONAL EXPERIENCE:

Current Academic Appointment

(2012-Present) Associate Clinical Professor, David Geffen School of Medicine at UCLA, Division of Hematology-Oncology

Previous Academic Appointments

(2005-2012) Assistant Clinical Professor, David Geffen School of Medicineat UCLA, Division of Hematology-Oncology

Current Administrative Appointment(s)

(2005-Present) Medical Director, UCLA Santa Monica Hematology & Oncology Practice

Research Interest

His research interests include: Antiphospholipid, Biliary, Breast, Cancers of the Digestive Tract, Chronic Myelogenous Leukemia, Colorectal (colon, rectum and anus), Esophageal, Gastric Cancer, Gastrointestinal Malignancies, General Hematology, General Oncology, Genitourinary, Geriatric Breast Cancer, Geriatric Prostate Cancer, Gynecologic Oncology, Head and Neck Oncology, Hematologic Malignancies, Hepatobiliary, Larynx, Leukemia, Liver, Lung, Lung Cancer & Chest Malignancies, Lymphoma, Mesothelioma, Multiple Myeloma, Ovarian Cancer, Pancreas, Prostate Cancer, Sickle Cell Anemia, Testicular Cancer, Thoracic Cancer, Unknown Primary, Waldenstroms Disease.

Scientific Activities

PROFESSIONAL ACTIVITIES:

Committee Service:

• 2010-Present: Member of Internal Scientific Peer Review Committee (ISPRC)

Community Service:

• 2009-Present: Medical Board Member of Persian American Cancer Institute (PACI)

Scholarly Societies:

• 1995-Present: Member of American Medical Student Association
• 1995-Present: Member of American Medical Association
• 1996-Present: Member of American College of Physicians
• 2005-Present: Member of American Society of Hematology
• 2005-Present: Member of American Society of Clinical Oncology

HONORS AND SPECIAL AWARDS:

• 1991-1995 (7/12 Quarters): Dean’s Honor List, University of California, Los Angeles
• 1992-Present: Golden Key National Honor Society
• 1994-Present: Phi Sigma Biology Honor Society
• June 1995: Chancellor’s Service Award, University of California, Los Angeles
• 1995: Phi Beta Kappa, Graduated Cum Laude and With Departmental Honors (Biology), University of California, Los Angeles
• January 1997: Winner, 3rd Place, AOA Research Competition, St. Louis University School of Medicine
• April 1998: Winner, Medical Student Research, Abstract Competition, American College of Physicians, 79th Annual Session, San Diego, California
• May 1999: Distinction in Research Award, St. Louis University School of Medicine
• Academic Year 2009-2010: UCLA Division of Hematology-Oncology Teacher of the Year

Publications

PEER-REVIEWED PUBLICATIONS

1. OBrien WA, Sumner-Smith M, Mao S-H, Sadeghi S, Zhao J-Q, Chen ISY. Anti-HIV-1 activity of an oligocationic compound is mediated via gp120 V3 interactions. J Virol. 1996; 70: 2825-2831.
2. Grovit-Ferbas K, Ferbas J, Gudeman V, et al. Potential contributions of viral and host genetic factors in a HIV-1 long term survivor. J Virol. 1998; 72(11): 8650-8658.
3. Hill DA, Sadeghi S, Schultz M, Burr J, Dehner LP. Pleuropulmonary Blastoma in the adult – An Initial Report. Cancer. 1999; 85(11): 2368-2374.
4. Levine AM, Sadeghi S, Espina B, Tulpule A, Nathwani B. Characteristics of indolent non-Hodgkins lymphoma in patients with type 1 Human Immunodeficiency Virus infection. Cancer. 2002; 94(5): 1500-1506.
5. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (Rituximab). Ann Rheum Dis. 2002; 61(10): 922-924.
6. Sadeghi S, Marder VJ, Stewart D, et al. Safety of Plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding. J Thromb Haemost. 2003; 1(12): 2621-2625.
7. Johnston S, Pippen J Hr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009; 27(33): 5492-5494. doi:10.1200/JCO.2009.23.3734.
8. Tsang RY, Sadeghi S, Finn RS. Lapatinib, a Dual-Targeted Small Molecule Inhibitor of Egfr and Her2, in Her2-Amplified Breast Cancer: From Bench to Bedside. Clinical Medicine Insights: Therapeutics. 2011; 3: 1-13.
9. Eiermann W, Pienkowski T, Crown J, et al. Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel as Adjuvant Treatment in Patients With HER2-Normal, Node-Positive Breast Cancer: Breast Cancer International Research Group (BCIRG)-005 Trial. J Clin Oncol. 2011; 29(29): 3877-3884.
10. Sadeghi S, Finn RS. Systemic therapy for cholangiocarcinoma. Clinical Liver Disease. 2014; 3(4): 86-89.
11. Macias MN, Shin DS, Ledezma B, Sadeghi S. Metastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin. BMJ Case Rep. 2014. doi:10.1136/bcr-2013-203400.
12. Sadeghi S, Olevsky O, Hurvitz SA. Profiling and targeting HER2-positive breast cancer using trastuzumabemtansine. Pharmgenomics Pers Med. 2014; 7: 329-338. doi:10.2147/PGPM.S47524.